World

EU approves Germany's 5-bln-euro subsidy for semiconductor plant

Aug 21, 2024

Brussels [Belgium], August 21: The European Union (EU) has approved a 5-billion-euro (5.56 billion U.S. dollars) state subsidy from Germany to support the construction and operation of a new microchip manufacturing plant, the European Commission announced on Tuesday.
The facility, known as the European Semiconductor Manufacturing Company, will be located in the city of Dresden in eastern Germany. It is expected to reach full operational capacity by 2029, with an annual production of 480,000 silicon wafers.
According to the European Commission, the plant will produce chips using 300 mm silicon wafers, with node sizes ranging from 28/22 to 16/12 nanometers, primarily targeting automotive and industrial applications.
The project aligns with the EU's plan of doubling its global market share in semiconductors to 20 percent by 2030, as outlined in the European Chips Act.
Europe has traditionally been reliant on the import of chips and wafers. The European automotive sector has been hard hit in recent years by a lack of semiconductors, severely limiting the industry's capacity.
Aiming to mobilize more than 43 billion euros from public and private investments, the European Commission introduced the EU Chips Act in 2022 to achieve its strategic independence from semiconductor imports, enabling it to react faster to supply chain issues. (1 euro = 1.11 U.S. dollar)
Source: Xinhua

More news

Hexaware and Abluva Join Forces to Deliver Secure Agentic AI Solutions for the Life Sciences Industry

Mumbai (Maharashtra) [India]/ Iselin (New Jersey) [US], July 10: Hexaware Technologies, a global provider of IT services and solutions, today announced a strategic partnership with Abluva, an innovator in agentic AI security, to address security challenges posed by autonomous AI agents in the Life Sciences industry. This collaboration brings together Hexaware's deep domain expertise and Abluva's groundbreaking Secure Intelligence Plane to help organizations in the sector deploy generative AI (GenAI) safely and in compliance with industry regulations. As Life Sciences organizations increasingly adopt agentic AI to enhance research, clinical trials, patient data management, and commercial operations, the partnership ensures that AI agents operate in a secure, governed, and auditable environment--without hindering innovation. Delivering Governed and Secure Generative AI Agents for Life Sciences Innovation.

Jul 10, 2025